KYMR has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
KYMR has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Kymera Therapeutics's enterprise value is $1,502.94 Mil. Kymera Therapeutics's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was $79.41 Mil. Therefore, Kymera Therapeutics's EV-to-Revenue for today is 18.93.
The historical rank and industry rank for Kymera Therapeutics's EV-to-Revenue or its related term are showing as below:
During the past 6 years, the highest EV-to-Revenue of Kymera Therapeutics was 131.77. The lowest was 5.66. And the median was 26.50.
The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.
EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.
As of today (2024-06-04), Kymera Therapeutics's stock price is $31.94. Kymera Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $1.33. Therefore, Kymera Therapeutics's PS Ratio for today is 24.07.
The historical data trend for Kymera Therapeutics's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kymera Therapeutics Annual Data | |||||||||||||||
Trend | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
EV-to-Revenue | Get a 7-Day Free Trial | - | 72.86 | 39.10 | 21.01 | 14.31 |
Kymera Therapeutics Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
EV-to-Revenue | Get a 7-Day Free Trial | 28.06 | 18.98 | 10.54 | 14.31 | 25.60 |
For the Biotechnology subindustry, Kymera Therapeutics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Kymera Therapeutics's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Kymera Therapeutics's EV-to-Revenue falls into.
EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.
Kymera Therapeutics's EV-to-Revenue for today is calculated as:
EV-to-Revenue | = | Enterprise Value (Today) | / | Revenue (TTM) |
= | 1502.944 | / | 79.413 | |
= | 18.93 |
Kymera Therapeutics's current Enterprise Value is $1,502.94 Mil.
Kymera Therapeutics's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $79.41 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kymera Therapeutics (NAS:KYMR) EV-to-Revenue Explanation
The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.
Kymera Therapeutics's PS Ratiofor today is calculated as:
PS Ratio | = | Share Price (Today) | / | Revenue per Share (TTM) |
= | 31.94 | / | 1.327 | |
= | 24.07 |
Kymera Therapeutics's share price for today is $31.94.
Kymera Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.33.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Kymera Therapeutics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Jeffrey W. Albers | director | BLUEPRINT MEDICINES CORP., 215 FIRST STREET, SUITE 340/350, CAMBRIDGE MA 02142 |
Ellen Chiniara | officer: Chief Legal Officer | 51 SAWYER ROAD, SUITE 200, WALTHAM MA 02453 |
Biotechnology Value Fund L P | other: See Explanation of Responses | 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104 |
Jeremy G Chadwick | officer: Chief Operating Officer | C/O KYMERA THERAPEUTICS, INC., 200 ARSENAL YARDS BLVD., SUITE 230, WATERTOWN MA 02472 |
Bruce N. Jacobs | officer: Chief Financial Officer | C/O KYMERA THERAPEUTICS, INC., 200 ARSENAL YARDS, SUITE 230, WATERTOWN MA 02472 |
Bruce Booth | director | 890 WINTER STREET, SUITE 320, WALTHAM MA 02451 |
Atlas Venture Fund X, L.p. | 10 percent owner | 400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139 |
Victor Sandor | director | C/O ARRAY BIOPHARMA INC., 3200 WALNUT STREET, BOULDER CO 80301 |
Leigh Morgan | director | KYMERA THERAPEUTICS, INC., 200 ARSENAL YARDS BLVD., SUITE 230, WATERTOWN MA 02472 |
John Maraganore | director | 75 SIDNEY ST, CAMBRIDGE MA 02139 |
Nello Mainolfi | director, officer: President and CEO | C/O KYMERA THERAPEUTICS, INC., 200 ARSENAL YARDS, SUITE 230, WATERTOWN MA 02472 |
Jared Gollob | officer: Chief Medical Officer | C/O KYMERA THERAPEUTICS, INC., 200 ARSENAL YARDS, SUITE 230, WATERTOWN MA 02472 |
Richard Chesworth | officer: Chief Scientific Officer | C/O KYMERA THERAPEUTICS, INC., 200 ARSENAL YARDS, SUITE 230, WATERTOWN MA 02472 |
Atlas Venture Associates X, L.p. | 10 percent owner | 400 TECHNOLOGY SQ., 10TH FLOOR, CAMBRIDGE MA 02139 |
Elaine Caughey | officer: Chief Business Officer | C/O KYMERA THERAPEUTICS, INC., 200 ARSENAL YARDS, SUITE 230, WATERTOWN MA 02472 |
From GuruFocus
By sperokesalga sperokesalga • 02-23-2023
By GuruFocus Research • 01-24-2024
By Value_Insider Value_Insider • 12-14-2022
By sperokesalga sperokesalga • 05-18-2023
By Marketwired • 08-03-2023
By sperokesalga sperokesalga • 06-14-2023
By Marketwired • 10-16-2023
By Marketwired • 09-18-2023
By Marketwired • 11-01-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.